UPH Stock: Why It Increased This Week

By Amit Chowdhry ● Oct 14, 2021
  • The stock price of UpHealth, Inc. (NYSE: UPH) increased by over 8% this past week. This is why it happened.

The stock price of UpHealth, Inc. (NYSE: UPH) increased by over 8% this past week. Investors are responding positively to UpHealth announcing an expansion of its NUTRAscriptives product line of clinical-grade supplements distributed online, in retail stores, and directly by providers. NUTRAscriptives Direct offers providers an easy-to-support business model to offer patients high-quality supplements to augment their care plans. And this new service further extends UpHealth leadership in the management of health with personalized protocols.

NUTRAscriptives Direct offers high-quality nutritional supplements available to providers with an easy-to-administer business model that enables patients to access provider-recommended supplements through any browser or a downloadable app to place orders. And NUTRAscriptives Direct drop ships the order for expedited shipping directly to patients and their families.

The NUTRAscriptives Direct service addresses a need of providers to offer clinical-grade nutritional supplements with no overhead or investment in inventory. And the new option supports additional revenue sources for providers with a proven return on investment (ROI) and gives providers the flexibility to choose which supplements they offer and adjust the price to support their unique market needs.

The new service and web/mobile application are currently in beta testing with providers. And NUTRAscriptives Direct will be rolled out to the provider community in the U.S. and Puerto Rico in Q1 2022.


“Our patients deserve the highest quality, potency and safety available. Clinically, I trust NUTRAscriptives as evidenced on lab values for my patients. I know these products are independently third-party tested for integrity. My patients are getting the quality they deserve.”

— Dr. Guy Domm, of Armur Medical, an innovative provider group working to improve health with an integrative approach

“NUTRAscriptives Direct responds to our customers’ need to provide high-quality clinical-grade supplements with an unwavering commitment to regulatory compliance, exceptional customer service, and national distribution capabilities. NUTRAscriptives Direct simplifies the ability for providers to offer our existing line of nutritional supplements with a business model that assures a solid ROI with virtually no overhead.”

— Mike Rolla, Chief Revenue Officer of UpHealth, Inc.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.